Journal of Research in Ayurvedic Sciences

Register      Login

VOLUME 3 , ISSUE 2 ( April-June, 2019 ) > List of Articles

PROTOCOL

Clinical Evaluation of Efficacy and Safety of Classical Ayurveda Formulations, Panchatikta Ghrita and Nalpamaradi Taila, in the Management of Psoriasis: A Study Protocol

Shruti Khanduri, Sophia Jameela, Hetal Amin, K Anumol, Bhogavalli Chandrasekhara Rao

Keywords : Dermatology life quality index, Nalpamaradi Taila, Panchatikta Ghrita, Psoriasis, Psoriasis area and severity index,Ayurveda

Citation Information : Khanduri S, Jameela S, Amin H, Anumol K, Rao BC. Clinical Evaluation of Efficacy and Safety of Classical Ayurveda Formulations, Panchatikta Ghrita and Nalpamaradi Taila, in the Management of Psoriasis: A Study Protocol. J Res Ayurvedic Sci 2019; 3 (2):68-73.

DOI: 10.5005/jras-10064-0079

License: CC BY-NC 4.0

Published Online: 00-06-2019

Copyright Statement:  Copyright © 2019; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Background: Psoriasis is a common immune-mediated dermatological manifestation that has a significant impact on the physical, social, and psychological well-being of the individual. The most common cutaneous manifestation of the disease includes chronic, symmetrical, scaling papules, and plaques on an erythematous base. Ayurveda considers skin disorders under the spectrum of Kushta and those diseases that manifest with dryness, exfoliation, thick plaques, etc., are generally attributed to vitiation of Vata and Kapha Dosha with underlying Rakta Dhatu Dushti. Panchatikta Ghrita has been used for both Shodhanartha Snehapana (oleation for Shodhana purpose) and Shamana in skin diseases of varied origin. Nalpamaradi Taila is ideal in vitiation of Vata and Kapha Dosha while pacifying Pitta and Rakta Dushti. Materials and methods: A multicenter, open-label prospective study that is to be executed at two Institutes of Central Council for Research in Ayurvedic Sciences (CCRAS) which were dedicated to research of skin disorders. A total of 120 patients would be recruited for the trial (60 from each institute) and would be administered with Panchatikta Ghrita in the dose of 6 g twice daily before food, with lukewarm water as Anupana, while Nalpamaradi Taila will be given for external application over the affected areas twice daily for a duration of 12 weeks. The primary outcome will be change in psoriasis area and severity index (PASI) score from baseline to final visit and change in dermatology life quality index (DLQI) questionnaire will be the secondary outcome measure. The safety and tolerability of the formulations will be determined by clinical/biochemical assessments during the follow-ups. Paired t test would be used to assess the efficacy of the interventions at 12th and 14th week when compared with the baseline. Data will be collected and analyzed at CCRAS Headquarters using SPSS 15.0 software. Ethics and dissemination: Ethics approval has been obtained from the participating institutes. The results obtained will be submitted for publication in a peer-reviewed journal. Trial registration number: CTRI/2020/01/022844.


PDF Share
  1. Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci 2019;20(6):E1475. DOI: 10.3390/ijms20061475.
  2. Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013;133(2):377–385. DOI: 10.1038/jid.2012.339.
  3. Gibbs S. Skin disease and socioeconomic conditions in rural Africa: Tanzania. Int J Dermatol 1996;35(9):633–639. DOI: 10.1111/j.1365-4362.1996.tb03687.x.
  4. Danielsen K, Olsen AO, Wilsgaard T, et al. Is the prevalence of psoriasis increasing? A 30-year follow-up of a population-based cohort. Br J Dermatol 2013;168(6):1303–1310. DOI: 10.1111/bjd.12230.
  5. Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician 2017;63(4):278–285.
  6. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009;361(5): 496–509. DOI: 10.1056/NEJMra0804595.
  7. Ko HC, Jwa SW, Song M, et al. Clinical course of guttate psoriasis: long-term follow-up study. J Dermatol 2010;37(10):894–899. DOI: 10.1111/j.1346-8138.2010.00871.x.
  8. Navarini AA, Burden AD, Capon F, et al. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol 2017;31(11):1792–1799. DOI: 10.1111/jdv.14386.
  9. Sommer DM, Jenisch S, Suchan M, et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006;298(7):321–328. DOI: 10.1007/s00403-006-0703-z.
  10. Ngan V. Guidelines for the management of psoriasis. Available from: https://dermnetnz.org/topics/guidelines-for-the-treatment-of-psoriasis/, last accessed 2019 December 16.
  11. Anonymous. The Ayurvedic Pharmacopoeia of India, Part II, vol. I, 1st ed. New Delhi: The Controller of Publications, Government of India; p. 80.
  12. Anonymous. The Ayurvedic Pharmacopoeia of India, Part II, vol. III, 1st ed. New Delhi: The Controller of Publications, Government of India; p. 88.
  13. Fredriksson T, Pettersson U. Oral treatment of pustulosis palmo-plantaris with a new retinoid, Ro 10-9359. Dermatologica 1979;158(1):60–64. DOI: 10.1159/000250744.
  14. Bożek A, Reich A. The reliability of three psoriasis assessment tools: psoriasis area and severity index, body surface area and physician global assessment. Adv Clin Exp Med 2017;26(5):851–856. DOI: 10.17219/acem/69804.
  15. Berth-Jones J, Grotzinger K, Rainville C, et al. A study examining inter- and intrarater reliability of three scales for measuring severity of psoriasis: psoriasis area and severity index, physician global assessment and lattice system physician global assessment. Br J Dermatol 2006;155(4):707–713. DOI: 10.1111/j.1365-2133.2006.07389.x.
  16. Finlay AY, Khan GK. Dermatology life quality index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19(3):210–216. DOI: 10.1111/j.1365-2230.1994.tb01167.x.
  17. Lewis-Jones MS, Finlay AY. The children's dermatology life quality index (CDLQI): initial validation and practical use. Br J Dermatol 1995;132(6):942–949. DOI: 10.1111/j.1365-2133.1995.tb16953.x.
  18. Hahn HB, Melfi CA, Chuang TY, et al. Use of the dermatology life quality index (DLQI) in a midwestern US urban clinic. J Am Acad Dermatol 2001;45(1):44–48. DOI: 10.1067/mjd.2001.110880.
  19. Reali E, Brembilla NC. Editorial: immunology of psoriatic disease. Front Immunol 2019;10:657. DOI: 10.3389/fimmu.2019.00657.
  20. Kayyadeva Nighantu, e-nighantu, ch. 1, Ver. 878–886. Available from: http://niimh.nic.in/ebooks/e-Nighantu/kaiyadevanighantu/?mod=read&h=nimb, last accessed on 2020 Jan 10.
  21. Kayyadeva Nighantu, e-nighantu, ch. 1, Ver. 562–567. Available from: http://niimh.nic.in/ebooks/e-Nighantu/kaiyadevanighantu/?mod=read&h=nimb, last accessed on 2020 Jan 10.
  22. Kayyadeva Nighantu, e-nighantu, ch. 1, Ver. 52–58. Available from: http://niimh.nic.in/ebooks/e-Nighantu/kaiyadevanighantu/?mod=read&h=nimb, last accessed on 2020 Jan 10.
  23. Kayyadeva Nighantu, e-nighantu, ch. 1, Ver. 7–11. Available from: http://niimh.nic.in/ebooks/e-Nighantu/kaiyadevanighantu/?mod=read&h=nimb, last accessed on 2020 Jan 10.
  24. Kayyadeva Nighantu, e-nighantu, ch. 1, Ver. 12–15. Available from: http://niimh.nic.in/ebooks/e-Nighantu/kaiyadevanighantu/?mod=read&h=nimb, last accessed on 2020 Jan 10.
  25. Kayyadeva Nighantu, e-nighantu, ch. 1, Ver. 221–234. Available from: http://niimh.nic.in/ebooks/e-Nighantu/kaiyadevanighantu/?mod=read&h=nimb, last accessed on 2020 Jan 10.
  26. Kayyadeva Nighantu, e-nighantu, ch. 1, Ver. 241–244. Available from: http://niimh.nic.in/ebooks/e-Nighantu/kaiyadevanighantu/?mod=read&h=nimb, last accessed on 2020 Jan 10.
  27. Kayyadeva Nighantu, e-nighantu, ch. 1, Ver. 235–240. Available from: http://niimh.nic.in/ebooks/e-Nighantu/kaiyadevanighantu/?mod=read&h=nimb, last accessed on 2020 Jan 10.
  28. Arya TU, Shailaja U, Arun Raj GR, et al. Exploratory study on the efficacy of Panchatiktaka Ghrita in the management of atopic dermatitis in children. Int J Res Ayurveda Pharm 2014;5(4):412–418. DOI: 10.7897/2277-4343.05485.
PDF Share